Scholarlink

Background <p>Although Arsenic trioxide (ATO) has revolutionized acute promyelocytic leukaemia (APL) from a uniformly fatal disease to one of the most curable leukemias, leukocytosis is a common life-threatening side effect and is associated with inferior results. This study aimed to describe leukocyte proliferation kinetics and explore predictors of leukocytosis among APL patients in order to guide individualized application of ATO.</p> Results <p>In this retrospective study of 100 patients, the incidence of leukocytosis in the single drug ATO group was 74.5%, while that in the ATO- chemotherapy group was 93.9% (<i>P</i> = 0.018). The dynamic changes in leukocytosis showed a higher WBC count in the ATO-chemotherapy group. The median time to leukocytosis was the 9th day (IQR, 6.00–14.00). The duration of leukocytosis was shorter in the ATO single agent group. The uni-variate analysis and multi-variable analysis showed that the same independent prognostic factor was <i>the time to double WBC</i> for leukocytosis for all patients (OR 11.459, 95% CI, 2.121–61.897) and ATO single agent patients (OR 16.603, 95% CI, 1.635-168.635). The area under the ROC curve was 0.835 (95% CI, 0.700-0.971) for all APL patients and 0.822 (95% CI, 0.675–0.969) for <i>single ATO-induced leukocytosis</i>.</p> Conclusions <p>The kinetics of leukocytosis induced by single-agent ATO and ATO-chemotherapy were different. <i>The time to double WBC≤7th day</i> was identified as an independent poor prognostic factor for single ATO-induced leukocytosis in APL patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors and kinetics of ATO-induced leukocytosis in acute promyelocytic leukemia patients: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • Hong Wei,
  • Zhuo Zhang,
  • Xueli Liu,
  • Qian Zhou,
  • Xin Zhang,
  • Ying Dong,
  • Siqi Zhai,
  • Qian Zhang,
  • Meijuan Sui

摘要

Background

Although Arsenic trioxide (ATO) has revolutionized acute promyelocytic leukaemia (APL) from a uniformly fatal disease to one of the most curable leukemias, leukocytosis is a common life-threatening side effect and is associated with inferior results. This study aimed to describe leukocyte proliferation kinetics and explore predictors of leukocytosis among APL patients in order to guide individualized application of ATO.

Results

In this retrospective study of 100 patients, the incidence of leukocytosis in the single drug ATO group was 74.5%, while that in the ATO- chemotherapy group was 93.9% (P = 0.018). The dynamic changes in leukocytosis showed a higher WBC count in the ATO-chemotherapy group. The median time to leukocytosis was the 9th day (IQR, 6.00–14.00). The duration of leukocytosis was shorter in the ATO single agent group. The uni-variate analysis and multi-variable analysis showed that the same independent prognostic factor was the time to double WBC for leukocytosis for all patients (OR 11.459, 95% CI, 2.121–61.897) and ATO single agent patients (OR 16.603, 95% CI, 1.635-168.635). The area under the ROC curve was 0.835 (95% CI, 0.700-0.971) for all APL patients and 0.822 (95% CI, 0.675–0.969) for single ATO-induced leukocytosis.

Conclusions

The kinetics of leukocytosis induced by single-agent ATO and ATO-chemotherapy were different. The time to double WBC≤7th day was identified as an independent poor prognostic factor for single ATO-induced leukocytosis in APL patients.